NasdaqGS:LIVNMedical Equipment
Will OSPREY Trial Data on aura6000 Sleep Apnea Device Change LivaNova's (LIVN) Narrative
LivaNova PLC recently reported that the Annals of Internal Medicine published 12‑month data from its OSPREY randomized controlled trial, showing sustained safety and clinically meaningful improvements in obstructive sleep apnea outcomes with the aura6000 proximal hypoglossal nerve stimulation system.
The publication underscores that aura6000 delivered benefits across a diverse, higher-risk patient group, including those with higher BMI and predicted complete concentric collapse, potentially...